How much did that home sell for? Check out recent property transfers in Buncombe County and Asheville, North Carolina.

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

As interest in the cancer-fighting potential of radiopharmaceutical drugs continues to swell, companies have unleashed a spate of investments in recent years to manufacture the nuclear medicines an | ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Aptamer Group plc, the developer of next‑generation synthetic binders for the life sciences industry, today announced the launch of a new targeted radiopharmaceutical program in collaboration with ...

Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug candidate 177Lu-SN201 ...

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Last week, the company got the FDA's tentative approval for the radioligand therapy, but a judge may soon decide whether it's ...

According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...